ANI Pharma Launches Erythromycin Ethylsuccinate For Oral Suspension, 200mg/5mL

(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) announced the launch of Erythromycin Ethylsuccinate for Oral Suspension 200mg/5mL indicated as a treatment for various infections. The current annual U.S. market for this product is approximately $78 million, according to IMS Health, and is representative of two brand products. ANI will immediately launch the product.

Erythromycin Ethylsuccinate for Oral Suspension is indicated in the treatment of infections caused by susceptible strains of selected diseases. For more information, including the complete list of indications and usages, please see the accompanying Full Prescribing Information.